Posters

      Quantitative Proteomics to Investigate the Effects of a Prototype Modified Risk Tobacco Product (pMRTP) and Smoking Cessation on Mouse Lung Proteome

      Dijon, S.; Elamin, A.; Titz, B.; Merg, C.; Geertz, M.; Schneider, T.; Martin, F.; Schlage, W.; Frentzel, S.; Talamo, F.; Veljkovic, E.; Ivanov, N. V.; Vanscheeuwijck, P.; Peitsch, M. C.; Hoeng, J.

      Conference date
      Sep 20, 2017
      Conference name
      HUPO 2017
      Link to more information
      Link to more information
      Topic
      Summary

      No abstract available.

      Related Publications

      Toxicological assessment of flavored e-liquids in Sprague Dawley rats in an OECD subchronic inhalation study complemented by systems toxicology endpoints

      Systems Toxicology Pre-clinical Toxicology

      Effects of aerosol from the Tobacco Heating System (THS) on human organotypic cultures of the aerodigestive tract

      Systems Toxicology Pre-clinical Toxicology

      Systems Toxicology In ApoE-/- Mice Demonstrates Smoking Cessation Benefits For Both Cardiovascular And Lung Disease-Related Endpoints

      Systems Toxicology Pre-clinical Toxicology

      Sytems toxicological-based assessment of sex-related differences in response to cigarette smoke within an OECD rat inhalation study

      Systems Toxicology Pre-clinical Toxicology

      Systems Toxicology Approaches Enable Mechanistic Comparison Of Cigarette Smoke-Induced And Spontaneous Lung Tumors In The A/J Mouse Model

      Systems Toxicology Pre-clinical Toxicology

      Physiologically based Pharmacokinetic Modeling of Nicotine from Inhaled Aqueous Aerosol Predicts Marked Gastrointestinal Absorption in Rats

      Systems Toxicology Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.